OGN (Osteoglycin), also known as Mimecan or SLRR3A, is a member of the small leucine-rich proteoglycan (SLRP) family and a glycosylated protein involved in the development of the extracellular matrix (ECM). It functions as a growth factor that induces bone formation in conjunction with TGF-beta-1 or TGF-beta-2 and may regulate osteoblast differentiation. OGN is expressed in various tissues and is implicated in multiple biological processes, including fibrosis, tumorigenesis, and cardiovascular events. High expression of OGN has been associated with elevated heart left ventricular mass and may play a role in the progression of certain cancers, such as pancreatic cancer, by targeting ID4. Additionally, OGN is detected in blood through mass spectrometry and proximity extension assays, indicating its potential as a biomarker in diseases like pediatric retinoblastoma.